µ-Theraphotoxin Pn3a inhibition of CaV3.3 channels reveals a novel isoform-selective drug binding site

Article
Figures and data
Abstract
Editor's evaluation
Introduction
Results
Discussion
Materials and methods
Data availability
References
Decision letter
Author response
Article and author information
Metrics

Abstract

Low voltage-activated calcium currents are mediated by T-type calcium channels Ca_V3.1, Ca_V3.2, and Ca_V3.3, which modulate a variety of physiological processes including sleep, cardiac pace-making, pain, and epilepsy. Ca_V3 isoforms’ biophysical properties, overlapping expression, and lack of subtype-selective pharmacology hinder the determination of their specific physiological roles in health and disease. We have identified μ-theraphotoxin Pn3a as the first subtype-selective spider venom peptide inhibitor of Ca_V3.3, with >100-fold lower potency against the other T-type isoforms. Pn3a modifies Ca_V3.3 gating through a depolarizing shift in the voltage dependence of activation thus decreasing Ca_V3.3-mediated currents in the normal range of activation potentials. Paddle chimeras of K_V1.7 channels bearing voltage sensor sequences from all four Ca_V3.3 domains revealed preferential binding of Pn3a to the S3-S4 region of domain II (Ca_V3.3^DII). This novel T-type channel pharmacological site was explored through computational docking simulations of Pn3a, site-directed mutagenesis, and full domain II swaps between Ca_V3 channels highlighting it as a subtype-specific pharmacophore. This research expands our understanding of T-type calcium channel pharmacology and supports the suitability of Pn3a as a molecular tool in the study of the physiological roles of Ca_V3.3 channels.

Editor's evaluation

Low voltage activated T-type calcium channels (CaV3.1-CaV3.3) are important to several physiological processes, but the functions of individual isoforms are difficult to distinguish pharmacologically. This study reports a spider toxin, Pn3a, which exhibits 100-fold selectivity for inhibiting CaV3.3 over CaV3.1 and CaV3.2 isoforms. This specificity is conferred by a specific interaction site on the Cav3.3 domain II voltage sensor.

https://doi.org/10.7554/eLife.74040.sa0

Introduction

Voltage-gated calcium (Ca_V) channels are activated by membrane depolarization and are involved in many physiological processes including contraction, secretion, neurotransmitter release, and gene expression (Catterall et al., 2005). In contrast to high voltage-activated (HVA) Ca²⁺ currents mediated by L-, N-, P/Q-, and R-type calcium channels that require large depolarizations, low voltage-activated (LVA) currents mediated by T-type Ca²⁺ channels are activated by small membrane depolarization and display distinctively faster activation and inactivation kinetics. T-type channel activation near resting membrane potentials generates low-threshold Ca²⁺ spikes responsible for the conspicuous burst firing and low-frequency oscillatory discharges observed in thalamic, olivary, and cerebellar neurons (Park et al., 2010; Dreyfus et al., 2010; Molineux et al., 2006; Lee et al., 2014). Thus, the biophysical properties of the T-type channels make them important regulators of cardiac and neuronal excitability (Perez-Reyes, 2003; Huguenard, 1996; Coulter et al., 1989) and therefore key pharmacological targets for the treatment of neurological and psychiatric disorders (Zamponi, 2016; Maksemous et al., 2022).

T-type calcium channels display small single-channel conductance (T stands for transient or tiny) (Perez-Reyes et al., 1998) and are encoded by the CACNA1G (Ca_V3.1), CACNA1H (Ca_V3.2), and CACNA1I (Ca_V3.3) genes. The Ca_V3s have similar channel activation and inactivation kinetics and are ubiquitously expressed in the nervous, neuroendocrine, reproductive, and cardiovascular systems (Perez-Reyes, 2003; Hansen, 2015). In heterologous expression systems, Ca_V3.3-mediated currents display the slowest activation and inactivation kinetics and recover faster from inactivation (Kozlov et al., 1999), however, due to these relatively small differences, they are nearly indistinguishable from the other T-type isoform in native tissue. In the brain, abundant CACNA1I transcripts display remarkable regional distribution and appear to prevail in distal dendrites (Perez-Reyes, 2003; Lee et al., 1999), where Ca_V3.3 currents mediate the major sleep-spindle pacemaker in the thalamus (Astori et al., 2011). Transgenic mice lacking Ca_V3.3 channels display severe alterations to sleep-spindle generator rhythmogenic properties posing this T-type channel isoform as a critical target in the study of brain function and development (Astori et al., 2011). However, the expression of Ca_V3.3 channels overlaps with that of Ca_V3.1 and/or Ca_V3.2, which together with the lack of robust, isoform-selective pharmacology has hampered the elucidation of their specific contributions to cellular physiology.

T-type calcium channels share the characteristic modular topology of other voltage-gated ion channels (VGICs) (Catterall et al., 2005) that consists of a voltage sensor (VS) module formed by transmembrane segments S1 through S4 and a pore module (PM) composed of the transmembrane segments S5 and S6 connected by a re-entrant pore loop. The VS controls channel opening in response to changes in membrane potential and the PM provides aqueous passage for ions across the lipid membrane. The tetrameric arrangement of four PMs lining the permeation pathway surrounded by four VSs in either swapped or non-swapped configuration enables VGIC function (for review, see Barros et al., 2019). In voltage-gated potassium (K_V) and transient receptor potential (TRP) channels, each monomer (1 × VS + 1 × PM) is encoded by a core α-subunit; whereas in voltage-gated sodium (Na_V) and Ca_V channels, the α-subunit contains the four homologous, but not identical, domains (DI-DIV) joined through large intracellular linkers (Catterall, 2000; Catterall et al., 2005).

Natural compounds that evolved to occlude ion channel’s PM or to interact with their VS are distinguished broadly as pore blockers and gating modifiers, respectively. In VGICs, the extracellularly exposed areas of the VS are pharmacological targets of neurotoxins and synthetic compounds where at least three distinct pharmacological sites have been described in Na_V channels (Catterall et al., 2007). Within the VS is a conserved S3b-S4 paddle motif which can be transplanted into the VS of other VGICs and retain toxin sensitivity (Bosmans et al., 2008). α-Scorpion toxins, sea-anemone toxins, and numerous spider toxins interact with Na_V channel site 3, located in the extracellular loop between DIV-S3 and DIV-S4 thereby interfering with the conformational changes that couple channel activation to fast inactivation (Hanck and Sheets, 2007). Binding of β-scorpion toxins to the S1-S2 and S3-S4 loops of domain II (site 4) shifts the voltage dependence of channel activation towards depolarized voltages reducing the maximal current at normal activation potentials. Lastly, pharmacological site 6 (located near site 3) is targeted by the δ-conotoxins that slow Na_V channel inactivation (Terlau et al., 1996). All these gating modifier peptides (GMPs) appear to ‘hold’ the VS in different conformations leading to their mechanism of modulation to be recognized as ‘VS trapping’ (Cestèle et al., 1998), a phenomenon also observed in the interaction of theraphotoxins with K_V2.1 (Swartz and MacKinnon, 1997) and agatoxins with Ca_V channels (McDonough et al., 1997a).

Sequence and functional conservation between the VSs lead to promiscuous interactions between peptides and small molecules across VGIC families. Examples of these include ProTx-I (Thrixopelma pruriens, Na_V/K_V/Ca_V/TRPA1) (Bladen et al., 2014; Bosmans et al., 2008; Gui et al., 2014; Middleton et al., 2002); ProTx-II (T. pruriens, Na_V/Ca_V) (Bladen et al., 2014; Middleton et al., 2002); Kurtoxin (Parabuthus transvaalicus, Na_V/Ca_V) (Chuang et al., 1998); Hanatoxin (Grammostola spatulata, K_V/Na_V/Ca_V) (Bosmans et al., 2008; Li-Smerin and Swartz, 1998; Swartz and MacKinnon, 1997), and Pm1a (Pelinobius muticus, Na_V/K_V) (Finol-Urdaneta et al., 2022). Furthermore, small molecules such as capsaicin, capsazepine (TRPV1/K_V/Ca_V) (Caterina et al., 1997; Kuenzi and Dale, 1996; McArthur et al., 2019), and A803467 (Na_V, Ca_V) (Bladen and Zamponi, 2012) amongst others are known to interact across VGIC families.

Shared ancestry and sequence conservation within the voltage sensing machinery have been used to rationalize commonalities in structure, gating kinetics, and pharmacophores between Na_V and T-type channels (Bladen and Zamponi, 2012). Several Na_V-active GMPs were shown to inhibit Ca_V3.1 channels through interactions with the channel’s domain III (Ca_V3.1^DIII) (Salari et al., 2016); whereas the potent Na_V1.7 inhibitor, µ-theraphotoxin Pn3a (Pamphobeteus nigricolour) (Deuis et al., 2017), also interacts with HVA Ca_V channels (McArthur et al., 2020).

In this study, we have used whole-cell patch clamp electrophysiology, mutagenesis, and computational docking to probe Pn3a’s interactions with the LVA Ca_V3 channels. Our results support the use of Pn3a as a molecular tool for the study of Ca_V3.3-mediated currents in native cells and highlight a previously unrecognized pharmacophore that may enable selective targeting of T-type channel isoforms.

Results

Pn3a selectively inhibits Ca_V3.3 channels

Functional assessment of Pn3a activity was examined on depolarization-activated calcium currents (I_Ca) through the human T-type calcium channel isoforms: Ca_V3.1, Ca_V3.2, and Ca_V3.3. Whole-cell currents were elicited by a 100 ms test pulse to −20 mV from a holding potential (Vh) of −90 mV at a frequency of 0.2 Hz and recorded at room temperature (20–22°C, Figure 1A). Pn3a (10 µM) strongly inhibited Ca_V3.3-mediated currents (90.2% ± 1.9%, n=5) with negligible effects over the two other T-type isoforms (Ca_V3.1: 3.8% ± 1.8%, n=5; Ca_V3.2: 2.5% ± 2.5%, n=5) (Figure 1A and B). These results indicate that Pn3a has >100-fold preference for Ca_V3.3 over the other highly homologous Ca_V3 isoforms. Scaled Ca_V3.3 macroscopic currents recorded in the absence (control) and presence of Pn3a (3 µM) display similar macroscopic activation kinetics (τ_{act, control} = 5.95 ± 0.54 ms vs. τ_{act, Pn3a} = 6.37 ± 0.44 ms; p=0.32, n=5, paired t-test), whereas Pn3a slowed macroscopic inactivation kinetics (τ_{inact control} = 39.91 ± 8.25 ms vs. τ_{inact, Pn3a} = 60.25 ± 16.02 ms; p=0.04, n=5, paired t-test) (representative currents provided in the inset, Figure 1A). The preferential actions of Pn3a highlight its potential as a molecular probe to isolate and study the contribution of Ca_V3.3 currents in native cells.

Figure 1

Download asset Open asset

Pn3a preferentially inhibits human Ca_V3.3-mediated Ca²⁺ currents.

(A) Ca_V3.3 (left), Ca_V3.1 (middle), and Ca_V3.2 (right) currents elicited by 100 ms step depolarization to −20 mV (Vh −90 mV, 0.2 Hz) in the absence (control, black) and presence of 3 µM Pn3a (pink). Scale bars: 0.2 nA, 20 ms. The inset shows scaled Ca_V3.3 currents in control and in the presence of Pn3a with similar kinetics. (B) Bar graph summarizing % inhibition by 10 µM Pn3a of the three Ca_V3 isoforms. (C) Concentration-response curve for Pn3a inhibition of Ca_V3.3 currents. (D) Kinetics of Pn3a inhibition of Ca_V3.3. K_obs was determined at three concentrations and fit with a linear equation where K_obs = k_on ∙ [Pn3a]+k_off. Data shown as mean ± SEM (n=5).

Figure 1—source data 1 Pn3a inhibition of T-type calcium channels.: https://cdn.elifesciences.org/articles/74040/elife-74040-fig1-data1-v2.xlsx
Download elife-74040-fig1-data1-v2.xlsx

Pn3a inhibitory potency against Ca_V3.3 currents was assessed at increasing peptide concentrations from which a concentration-response curve was built (Figure 1C). Fit to a standard Hill equation rendered an IC₅₀ value of 0.96±0.05 µM (nH 0.87±0.04, n=5 per concentration) for the inhibition of Ca_V3.3 channels. This Hill coefficient is consistent with a 1:1 stoichiometry between Pn3a toxin and Ca_V3.3 channels.

The change in Ca_V3.3 peak current amplitude during Pn3a washin and washout enables the assessment of Pn3a binding to Ca_V3.3 channels. The inhibition of Ca_V3.3 I_Ca by Pn3a was mono-exponential with progressively faster time constants (τ_obs) at increasing peptide concentration (Figure 1D). The on- and off-rate constants (k_on and k_off) were determined from the fit to the linear plot of 1/τ_obs vs. [Pn3a] (Figure 1D, n=5 per concentration), where k_on is the slope and k_off is the y-intercept. The linear regression line results in a k_on of 0.036 µM^–1 s^–1 and k_off of 0.052 s^–1 which yield a K_D of 1.4 µM, in close agreement with the IC₅₀ value obtained (Figure 1C). k_off was confirmed by fitting the washout to a single exponential (k_off = 0.055 ± 0.002 s^–1). Hence, Pn3a inhibits Ca_V3.3-mediated currents without apparent actions on Ca_V3.1 or Ca_V3.2 exposed to up to 10 µM peptide.

Pn3a modifies the gating of Ca_V3.3

The voltage dependence of Ca_V3.3 activation, deactivation, inactivation, and recovery from inactivation were investigated in the absence and presence of Pn3a (3 µM) (Figure 2 and Table 1). Ca_V3.3 activation is shifted ~13 mV to more depolarized potentials (control V_0.5 = −28.3±0.4 mV, n=5, vs. Pn3a V_0.5 = −15.3±0.4 mV, n=5; p<0.0001), indicating that a stronger depolarization is required to enable channel opening in the presence of Pn3a (Figure 2A and C). The voltage dependence of Ca_V3.3 steady-state inactivation (SSI) was not affected by exposure to the spider peptide (control V_0.5 = −56.3±0.3 mV, n=5, vs. Pn3a V_0.5 = −56.6±0.4 mV, n=5, p=0.57, Figure 2B–C). Consistent with the observed slowing of inactivation, Ca_V3.3-mediated currents inactivated by a 200 ms pre-pulse to –20 mV recovered faster in the presence of Pn3a (τ=0.22 ± 0.01 s, n=5) than under control conditions (τ=0.34 ± 0.01 s, n=5; p<0.0001) (Figure 2D–E), suggesting a potential Pn3a-dependent destabilization of the inactivated state.

Figure 2 with 1 supplement see all

Download asset Open asset

Pn3a produces a depolarizing shift in the voltage dependence of activation and speeds up recovery from inactivation of Ca_V3.3.

(**A–C**) Effect of Pn3a on the voltage dependence of Ca_V3.3. Representative currents from (A) activation or (B) steady-state inactivation protocols, in the absence (top: control, black) and presence of 3 µM Pn3a (middle: Pn3a, pink) using the standard protocols (bottom). Scale bars: 0.5 nA, 10 ms. (C) Activation (circles) and steady-state inactivation (squares) relationships for Ca_V3.3 in the absence (black) and presence of 3 µM Pn3a (pink). Dashed lines represent non-normalized activation and inactivation curves of Pn3a. (D) Representative recovery from inactivation currents in control (left) and presence of 3 µM Pn3a (right) (trace shown in blue highlights the current recovered after 0.3 s). Scale bars: 0.2 nA, 200 ms. (E) Recovery from inactivation in the absence (black) and presence of 3 µM Pn3a (pink). Data shown as mean ± SEM (n=5).

Figure 2—source data 1 Pn3a voltage effects o activation, steady-state inactivation, and recovery from inactivation.: https://cdn.elifesciences.org/articles/74040/elife-74040-fig2-data1-v2.xlsx
Download elife-74040-fig2-data1-v2.xlsx

Table 1

Activation and inactivation values of Ca_V3.3 and K_v1.7-Ca_V3.3^DI-IV chimers in the absence (control) and presence of Pn3a (3 µM for Ca_V3.3; 1 µM for K_V1.7-Ca_V3.3^D1-IV chimeras).

		Control Pn3a
hCa_V3.3	V_0.5 activation	−28.3±0.4 mV (5)	−15.3±0.4 mV (5) *
	ka Slope factor	7.5±0.3 (5)	10.0±0.3 (5) *
	V_0.5 SSI	−56.3±0.3 mV (5)	−56.6±0.4 mV (5)
	ka Slope factor	7.5±0.2 (5)	8.4±0.4 (5)
	τ Recovery	0.34±0.01ms (5)	0.22±0.01 (5) *
K_V1.7	V_0.5 activation	−10.5±0.6 mV (7)	-
K_V1.7	ka Slope factor	9.9±0.5 (7)	-
K_V1.7-Ca_V3.3^DI	V_0.5 activation	91.3±0.4 mV (5)	88.2±0.3 mV (5)
K_V1.7-Ca_V3.3^DI	ka Slope factor	1.0±0.3 (5)	11.8±0.2 (5)
K_V1.7Ca_V3.3^DII	V_0.5 activation	97.3±0.4 mV (9)	112.6±0.4 mV (7) *
K_V1.7Ca_V3.3^DII	ka Slope factor	14.1±0.3 (9)	12.3±0.4 (7) *
K_V1.7-Ca_V3.3^DIII	V_0.5 activation	71.3±0.8 mV (7)	74.7±0.9 mV (5)
K_V1.7-Ca_V3.3^DIII	ka Slope factor	21.1±0.7 (7)	22.0±0.8 (5)
K_V1.7-Ca_V3.3^DIV	V_0.5 activation	−60.8±0.8 mV (5)	−60.8±0.4 mV (5)
K_V1.7-Ca_V3.3^DIV	ka Slope factor	10.1±0.7 (5)	10.0±0.4 (5)

*

Significant determined from paired t-test with significance threshold set to p<0.05.

The voltage dependence of Pn3a inhibition of I_Ca and Na⁺-mediated (I_Na) Ca_V3.3 currents was examined at various test potentials (Figure 3A and Figure 3—figure supplement 1). Pn3A displayed a decrease in Ca_V3.3 I_Ca inhibition at more depolarized potentials consistent with Pn3a preferentially binding to the down-state of the VS. To examine the voltage dependence across a larger voltage range, extracellular Ca²⁺ was removed, permitting Na⁺ to be the primary charge carrier through the open Ca_V3.3. Similar to that seen for I_Ca, I_Na showed a similar voltage dependence, with stronger inhibition at more negative potentials (Figure 3—figure supplement 1).

Figure 3 with 1 supplement see all

Download asset Open asset

Pn3a inhibition of Ca_V3.3 is stronger at hyperpolarized potentials and speeds up channel deactivation.

(A) Voltage dependence of Pn3a inhibition of Ca_V3.3-mediated Ca²⁺ currents. (B) Representative Ca_V3.3 tail currents at different voltages in the absence (black) and presence (pink) of 3 µM Pn3a. (C) Summary of the time constant (τ) of Ca_V3.3 deactivation upon return to the holding potential (−90 mV) plotted against the activating (pre-pulse) potential in the absence (control, black) and the presence of Pn3a (3 µM, pink). Data shown as mean ± SEM (n=5).

Figure 3—source data 1 Voltage dependence of Pn3a inhibition.: https://cdn.elifesciences.org/articles/74040/elife-74040-fig3-data1-v2.xlsx
Download elife-74040-fig3-data1-v2.xlsx

The time course of tail current decay reflects the rate of channels leaving the open state (test potential) and entering the closed state (deactivation) upon return to the holding potential. We examined the modulation of Ca_V3.3 channel deactivation through tail current kinetic analysis. Pn3a-modified Ca_V3.3 currents displayed a faster deactivation time constant (τ_deactivation) across all potentials tested compared to control (Figure 3B–C). This data suggests that Pn3a binding may destabilize the open state or stabilize the closed one. This results that Pn3a is a Ca_V3.3 GMP that decreases channel availability by increasing the energy required for channel opening.

Pn3a interacts with Ca_V3.3^DII S3-S4 paddles

To ascertain Pn3a’s pharmacophore on Ca_V3.3 channels, we applied the chimeric approach of transplanting its four S3-S4 paddles into a K_V channel based on a similar template to that previously described for K_V2.1/Ca_V3.1 chimeras (Salari et al., 2016). We substituted portions of the S3b-S4 from Ca_V3.3 DI to DIV into the K_V1.7 channel backbone. The sequence alignment of Ca_V3.3 DI-DIV S3-S4 segments and the corresponding extracellular region of K_V1.7 is presented in Figure 4A.

Figure 4

Download asset Open asset

Chimeric constructs of the K_V1.7 channel with the Ca_V3.3 voltage sensor paddles.

(A) Sequence alignment between paddle regions of Ca_V3.3 and K_V1.7. The coloured bolded sequences from Ca_V3.3 DI (yellow), Ca_V3.3 DII (pink), Ca_V3.3 DIII (blue), and Ca_V3.3 DIV (green) were grafted onto K_V1.7 (black). (B) Representative current traces in response to 50 ms long I-V protocols used to evaluate the voltage dependence of activation of all constructs (Vh = −80 mV). K_V1.7/Ca_V3.3^DI (0–160 mV), K_V1.7/Ca_V3.3^DII (0–160 mV), K_V1.7/Ca_V3.3^DIII (0–160 mV) and K_V1.7/Ca_V3.3^DIV (−120 to 30 mV). The traces highlighted in colour correspond to currents near half-activation potential (V_0.5). (C) Activation curves for all chimeras: K_V1.7/Ca_V3.3^DI (yellow), K_V1.7/Ca_V3.3^DII (pink), K_V1.7/Ca_V3.3^DIII (blue), and K_V1.7/Ca_V3.3^DIV (green) and the parental channel K_V1.7 (black). The dotted line corresponds to Ca_V3.3 activation for reference. The inset contains representative K_V1.7 currents (−60 to 90 mV). All scale bars: 1 nA, 10 ms.

All four K_V1.7/Ca_V3.3 chimeric constructs were functional, mediating large K⁺ currents that displayed distinct gating properties from those of the parental wild-type K_V1.7 (V_0.5 = −10.5±0.6 mV, n=7; Figure 4B, inset). Briefly, chimeric K_V1.7/Ca_V3.3^DI, K_V1.7/Ca_V3.3^DII and K_V1.7/Ca_V3.3^DIII displayed 80–100 mV depolarizing shifts in channel activation (K_V1.7/Ca_V3.3^DI V_0.5=91.3 ± 0.4 mV, n=5; K_V1.7/Ca_V3.3^DII V_0.5=97.3 ± 0.4 mV, n=9; K_V1.7/Ca_V3.3^DIII V_0.5=71.3 ± 0.8 mV, n=7, two-way ANOVA, p<0.05), whereas K_V1.7/Ca_V3.3^DIV activation was ~50 mV hyperpolarized (K_V1.7/Ca_V3.3^DIV V_0.5 = −60.8±0.8 mV, n=5; two-way ANOVA, p<0.05) (Figure 4). Our results are in broad agreement with previous reports for Ca_V3.1, where DIV displays a hyperpolarizing shift and DI-III show a variable depolarizing shift in V_0.5 (Salari et al., 2016).

K_V1.7/Ca_V3.3^DI-IV chimeras and the parental K_V1.7 construct were analysed in control and after exposure to Pn3a (1 µM) and representative currents (Vh = −100 mV, with test pulse to +40 mV (K_V1.7), +120 mV (K_V1.7/Ca_V3.3^DI-III), or 0 mV (K_V1.7/Ca_V3.3^DIV)) in both conditions are included as insets (Figure 5). Similar to the parental channel, peak currents of K_V1.7/Ca_V3.3^DI and K_V1.7/Ca_V3.3^DIV chimaeras were insensitive to Pn3a (K_V1.7: 1.0% ± 0.8%, n=6; Ca_V3.3^DI: 0.6% ± 0.5%, n=5, and Ca_V3.3^DIV: 0.4% ± 0.2%, n=5) (Figure 5A, D and E), with K_V1.7/Ca_V3.3^DIII displaying modest peptide-dependent inhibition (12.0% ± 0.6%, n=6) (Figure 5C).

Figure 5 with 1 supplement see all

Download asset Open asset

Pn3a shifts the activation of K_V1.7/Ca_V3.3^DII chimeric channels.

G/G_max-V relationships and representative currents obtained in the absence (control, black) and presence of 1 µM Pn3a (pink) for (A) K_V1.7/Ca_V3.3^DI (90 mV), (B) K_V1.7/Ca_V3.3^DII (100 mV), (C) K_V1.7/Ca_V3.3^DIII (70 mV), and (D) K_V1.7/Ca_V3.3^DIV (−60 mV). (E) Bar graph showing percent inhibition by 1 µM Pn3a of K_V1.7/Ca_V3.3^DI-IV chimeras and K_V1.7 wt. (F) K_V1.7 G/G_max-V relationship and current traces obtained in the absence (control) and presence of Pn3a (–10 mV). All scale bars: 1 nA, 10 ms.

Figure 5—source data 1 Voltage dependence of Pn3a inhibition of Kv1.7/Cav3.3 Chimera.: https://cdn.elifesciences.org/articles/74040/elife-74040-fig5-data1-v2.xlsx
Download elife-74040-fig5-data1-v2.xlsx

In contrast, currents mediated by K_V1.7/Ca_V3.3^DII were significantly reduced (54.2% ± 2.9%, n=7) in the presence of Pn3a (Figure 5B). Furthermore, conductance-voltage relationships for each S3-S4 paddle chimera in the absence and presence of Pn3a were built from peak currents in response to standard I-V protocols (K_V1.7 –60 to +90 mV; K_V1.7/Ca_V3.3^DI-III 0 to +160 mV; and K_V1.7/Ca_V3.3^DIV −120 to +30 mV; Vh = −100 mV, 0.2 Hz). The latter analysis revealed an ~15 mV rightward shift in the half voltage of activation (V_0.5) exclusively in the Ca_V3.3^DII chimera when exposed to Pn3a (control V_0.5=97.3 ± 0.4 mV, n=9; vs. Pn3a V_0.5=112.6 ± 0.4 mV, n=7, p<0.0001), strongly suggesting that Pn3a interacts with the S3-S4 region of domain II in Ca_V3.3. These results suggest that the positive shift in activation V_0.5 observed in the full length and DII chimera likely underpins Pn3a’s mechanism of Ca_V3.3 inhibition, highlighting the differences in pharmacological properties of each voltage-sensing module.

Molecular determinants of Pn3a inhibition of Ca_V3.3

The critical role of DII was further supported by examining the effects of Pn3a on full-length Ca_V3 channel constructs where the whole DII was swapped between isoforms. Replacement of Ca_V3.3^DII with either Ca_V3.1^DII or Ca_V3.2^DII resulted in partial (Ca_V3.3/Ca_V3.1^DII: 33% ± 4.1%, n=5, one-way ANOVA p<0.0001) or complete (Ca_V3.3/Ca_V3.2^DII: 2.2% ± 1.5%, n=5, one-way ANOVA p<0.0001) loss of inhibition compared to the full-length Ca_V3.3 (90.2 ± 1.9% n=5) in the presence of 10 μM Pn3a (Figure 6E). The reverse constructs where Ca_V3.3^DII was grafted onto Ca_V3.1 (Ca_V3.1/Ca_V3.3^DII) or Ca_V3.2 (Ca_V3.2/Ca_V3.3^DII) afforded Pn3a sensitivity to the parental Ca_V3 channel such that currents mediated by Ca_V3.1/Ca_V3.3^DII were inhibited by 71.4% ± 4.1% (n=5), and Ca_V3.2/Ca_V3.3^DII by 68.0% ± 3.6% (n=5) (Figure 6F). Thus, verifying that Ca_V3.3^DII is required for Pn3a interaction with T-type calcium channels.

Figure 6 with 3 supplements see all

Download asset Open asset

Pn3a and Ca_V3.3 interactions and subtype specificity.

(A) Top view of Pn3a (magenta) binding to Ca_V3.3^DII. The S3 (lime), S3-4 loop (ice blue), and S4 (pink) are highlighted. (B) Side view of the binding conformation of Pn3a to Ca_V3.3^DII. (C) Left: Pn3a amino acid sequence and disulfide connectivity. Right: 3D structure of Pn3a (PDB ID: 5T4R Deuis et al., 2017) showing cysteine residues in CPK linked by salt bridges (yellow). (D) Pairwise amino acid interactions between Pn3a (magenta) with the extracellular loop of Ca_V3.3^DII (top left, blue), Ca_V3.2^DII (top right, yellow), and Ca_V3.1^DII (bottom left, purple). Overlap of the Pn3a-bound ribbon structures of all Ca_V3 highlighting differences in extracellular S3-S4 loops between Ca_V3.3 and the other two Ca_V3 isoforms (bottom right). S1, S1-2 loop, and S2 were removed for clarity. (E) Bar graph showing percent inhibition by 10 µM Pn3a of Ca_V3^DII domain-swapped Ca_V3 constructs and point mutants.

Figure 6—source data 1 Pn3a docking coordinates for T-type calcium channels.: https://cdn.elifesciences.org/articles/74040/elife-74040-fig6-data1-v2.zip
Download elife-74040-fig6-data1-v2.zip

Molecular docking was used to assess the most energetically favoured binding poses for Pn3a on the extracellular-facing pockets of DII of the three channel isoforms, Ca_V3.3, Ca_V3.2, and Ca_V3.1 (Figure 6 and Figure 6—figure supplements 1–3). Comparative analyses of toxin interactions with the other T-type calcium channel members showed that Pn3a forms fewer contacts with the DII S3-S4 linker of Ca_V3.1 and Ca_V3.2, compared to Ca_V3.3 (Figure 6D). Evaluation of the inter-residue contacts between the docked Pn3a and Ca_V3.3^DII revealed several receptor residues predicted to form close contacts with the toxin (Figure 6D, upper left inset). In particular, Pn3a-K17 is predicted to be in close proximity to D689 and may form an especially strong interaction due to the possibility of a salt bridge contact. Guided by the docking results, point mutations of selected Cav3.3^DII amino acids (E628A, Q687A, D689A, R696A, K1294A, N1310A, and Q1362A) were explored within full-length Cav3.3 channels. In comparison to wild-type Ca_V3.3, Ca_V3.3-D689A (27.6% ± 1.8%, n=5, one-way ANOVA p<0.0001) and Ca_V3.3-E628A (68.2% ± 2.0%, n=5, one-way ANOVA p<0.0001) displayed significant reductions in Pn3a inhibition (Figure 6F), whereas the peptide activity in the other mutants studied (Ca_V3.3-Q687A: 83.6% ± 0.5%, n=5; Ca_V3.3-R696A: 83.6% ± 2.7%, n=5; Ca_V3.3-K1294A: 84.8% ± 1.2%, n=5; Ca_V3.3-N1310A 79.2% ± 3.5%, n=5; and Ca_V3.3-Q1362A 85.4% ± 1.3%, n=5) was unaffected. The relevance of Ca_V3.3-D689 interaction with Pn3a was further substantiated by the loss of inhibition in the analogous charge neutralization K_V1.7/Cav3.3^DII chimeric construct K_V1.7/Ca_V3.3^DII-D262A (Figure 5—figure supplement 1), thus pinpointing key molecular determinants responsible for Pn3a’s selective inhibition of Ca_V3.3.

Discussion

The present study demonstrates the functional activity of Pn3a as a gating modifier inhibitor of human Ca_V3.3 channels with >100-fold higher activity over Ca_V3.1 and Ca_V3.2. Our chimeric approaches revealed Pn3a’s preference for Ca_V3.3^DII S3-S4 paddle region, whereas comparative molecular docking amongst isoforms identified a novel binding site putatively determining Pn3a’s proclivity towards Ca_V3.3. Thus, this investigation highlights Pn3a as the first molecular probe available for the study of Ca_V3.3 contribution in native cells. We propose that the unique features of Pn3a’s Ca_V3.3 specificity may be exploited to design isoform-selective T-type calcium channel modulators.

Ca_V3 subtype selectivity

µ-Theraphotoxin Pn3a was originally described as a potent Na_V1.7 inhibitor with an IC₅₀ of 0.9 nM, while also inhibiting other tetrodotoxin-sensitive Na_V channels (Na_V1.1–1.4 and Na_V1.6) with 10- to 100-fold less potency (Deuis et al., 2017). More recently Pn3a was shown to inhibit murine dorsal root ganglion HVA I_Ca and human Ca_V1.2, Ca_V1.3, Ca_V2.1, and Ca_V2.2 calcium channels expressed in HEK293T cells (IC₅₀ 3–10 μM) (McArthur et al., 2020). Perhaps a more interesting aspect of Pn3a activity is its >100-fold selectivity for human Ca_V3.3 over both Ca_V3.1 and Ca_V3.2 (Figure 1) which distinguishes this spider peptide as a unique isoform-selective modulator of T-type calcium channels. Only a handful of venom-derived peptides have been shown to interact with T-type calcium channels. The scorpion peptide Kurtoxin was the first GMP reported to modulate Ca_V3 channels with a high affinity for Ca_V3.1 and Ca_V3.2 channels (Chuang et al., 1998). The closely related peptide KLI, from Parabuthus granulatus, was later shown to inhibit Ca_V3.3 with an IC₅₀ ~ 450 nM (Olamendi-Portugal et al., 2002). However, the T-type isoform selectivity and binding site of these two peptides were not comprehensively documented at the time. The activity of spider Protoxins I and II against the three Ca_V3 channels revealed that ProTx-I preferentially modulates Ca_V3.1 channels, whereas ProTx-II targets Ca_V3.2 (Bladen et al., 2014; Salari et al., 2016). Thus, Pn3a complements the molecular toolbox for the study of T-type calcium channels in native tissues.

Voltage dependence and current kinetics

Pn3a inhibits Ca_V3.3 by inducing a depolarizing shift in Ca_V3.3 voltage dependence of activation in a manner analogous to Kurtoxin, Protoxin I, and Protoxin II actions on Ca_V3.1 channels (Edgerton et al., 2010; Chuang et al., 1998). This is also consistent with Pn3a’s modulation of Na_V1.7 (Deuis et al., 2017) but not of Ca_V2.2 channels for which a hyperpolarizing shift in the voltage dependence of inactivation was associated with current inhibition (McArthur et al., 2020). In contrast to the twofold slower recovery from inactivation reported for Pn3a-bound Na_V1.7 channels, currents mediated by Pn3a-modified Ca_V3.3 channels recover ~1.5-fold faster from inactivation (Figure 2D/E). This and the observed slowing of inactivation (at high Po) are suggestive of a toxin-induced destabilization of the inactivated state. Nevertheless, given Pn3a’s voltage dependence of Cav3.3 inhibition (Figure 3A), voltage-dependent unbinding of the toxin at more positive potentials could also contribute to an apparent faster recovery from inactivation as reported for Ca_V active toxins such as AgaIVA (McDonough et al., 1997b) and SNX482 (Bourinet et al., 2001).

Pn3a inhibition of Ca_V3.3 was voltage-dependent with greater inhibition at more negative potentials (Figure 3A) similar to Kurtoxin-inhibited Ca_V3.1 channel currents (Chuang et al., 1998). However, a delay in Ca_V3.1 activation kinetics was apparent in the presence of both Kurtoxin and ProTx-II (Edgerton et al., 2010; Chuang et al., 1998) but not in Pn3a-modified Ca_V3.3. The spider peptides Pn3a (this study) and ProTx-II (Edgerton et al., 2010) appear to slow T-type channel deactivation suggestive of stabilization of the channel’s closed state, whereas Kurtoxin, from scorpion venom, does not affect Ca_V3.1 channel closure (Chuang et al., 1998) highlighting incompletely understood aspects of GMP/VGIC interactions.

Interaction of Pn3a with Ca_V3.3 VS paddles

The portability of the S3-S4 paddle region was shown more than 20 years ago (Swartz and MacKinnon, 1997). To date, most studies, if not all, have used the K_V2.1 channel backbone for the identification of GMPs binding sites in Na_V and Ca_V channels expressed in Xenopus oocytes (Bosmans et al., 2008; Salari et al., 2016). For our chimera studies, we selected the K_V1.7 backbone given the remarkable scarcity of GMPs interacting with K_V1 channels (Finol-Urdaneta et al., 2020). The robust expression of this channel in heterologous systems (Finol-Urdaneta et al., 2006; Finol-Urdaneta et al., 2012) and resistance to Pn3a modulation (Figure 5E/F) make it suitable to assess peptide binding to Ca_V3.3 paddle motifs in mammalian cells. The generated K_V1.7/Ca_V3.3 constructs resulted in four functional, voltage-gated chimeric potassium channels that exhibited distinct gating properties to those of the parental scaffold reflecting the acquisition of the grafted S3-S4 paddle regions from DI to DIV of Ca_V3.3. Namely, K_V1.7/Ca_V3.3^DI-DIII all displayed >80 mV depolarizing shifts in channel activation compared to wild-type K_V1.7, whereas the Ca_V3.3^DIV bearing chimeric construct presented a comparable magnitude shift in the hyperpolarizing direction (Figure 4).

Analogous chimeric approaches of K_V2.1/Ca_V3.1D^I-IV have indicated that ProTx-II, PaTx-1, GsAF-I, and GsAF-II exert their inhibitory actions predominantly through interaction with Ca_V3.1^DIII (Salari et al., 2016), whereas Pn3a does so by targeting K_V2.1/Na_V1.7^DII and K_V2.1/Na_V1.7^DIV (Deuis et al., 2017). Here, we observe modest Pn3a inhibition of K_V1.7/Ca_V3.3^DIII-mediated currents and potent effects on K_V1.7/Ca_V3.3^DII chimeras with current inhibition coupled to toxin-induced rightward shift in the voltage dependence of activation as evidence of preferential interactions with Ca_V3.3^DII (Figure 5B/F). A substantial body of literature has shown that DI-DIII and DIV are important for Na_V activation and inactivation, respectively (Ahern et al., 2016). Thus, the predominant effects of Pn3a on Ca_V3.3 activation are consistent with its interaction with DII of this channel.

Furthermore, it has been shown that ProTx-I inhibits Ca_V3.3/Ca_V3.1^DIV chimeric channels while interacting less potently with Ca_V3.3/Ca_V3.1^DII. However, a clear binding site could not be delineated through mutation of individual Ca_V3.1^DII residues as those did not result in measurable changes in toxin affinity (Bladen et al., 2014). Our domain swap experiments verified that Pn3a’s actions are largely determined by Ca_V3.3^DII from which aspartate in position 689 constitutes an important interaction site as shown by its alanine replacement in Ca_V3.3 and K_V1.7/Ca_V3.3^DII. It can be surmised that subtle, but significant GMP/VGIC interaction differences highlight incompletely understood idiosyncrasies related to molecular aspects of ion channel function between isoforms as well as how peptide interactions may be affected by the experimental manipulation and conditions used for their study.

A novel binding site with Ca_V3 subtype selectivity

Our molecular docking calculations suggest that Pn3a binds within the groove formed between extracellular linkers S1-S2 and S3-S4 supported by electrostatic interactions with the Ca_V3.3^DII S3-S4 paddle, which bears some similarity with the Ca_V3.1/ProTx-II complex in which favourable binding sites occur in Ca_V3.1’s DII and DIV (Bladen et al., 2014).

The interaction of Pn3a with Ca_V3.3 channels involves substantial interactions within the S3-S4 paddle (K17-Q687) and S4 (H18-R696) of Ca_V3.3^DII, while a close contact may also exist between the sidechain of D689 and the sidechain of Pn3a-K17 (Figure 6D, upper left panel). The latter is consistent with the establishment of a salt bridge between these residues. The loss of Pn3a inhibition upon charge neutralization at this position lends support to this docking model.

The proximity between cationic residues (K17 and H18) on loop 3 of Pn3a and the Ca_V3.3D^II S3-S4 paddle places this peptide at the hollow between S1-S2 and S3-S4 linkers in a binding conformation similar to other tarantula toxins targeting Na_V channel site 4, like HwTX-IV, ProTx-II, and HNTX-III, that bear critical basic and hydrophobic amino acids within loop 4 that interact with acidic residues on the Na_V^DII’s S3-S4 linker (Deng et al., 2013; Liu et al., 2013; Bosmans and Swartz, 2010; Figure 6—figure supplements 1 and 2). Hence, the predicted Pn3a interaction with Ca_V3.3 appears to share overall similarities with previously identified spider peptide toxins modulating Na_V and K_V channels in which the common bioactive surface consists of positively charged and hydrophobic residues (Smith et al., 2007; Corzo et al., 2005).

The findings presented here establish Pn3a as a gating modifier modulator of Ca_V3.3 channels interacting with the paddle motif of DII’s VS module through putative stabilization of the closed/resting state and concomitant channel current inhibition. Pn3a’s>100-fold higher potency against Ca_V3.3 over the other two Ca_V3 isoforms is rationalized through recognition of a previously unknown drug binding site that may be exploited in the design of isoform-selective Ca_V3 channel modulators.

Materials and methods

Cell lines, culture, and transfections

Request a detailed protocol

Human embryonic kidney (HEK293T, authenticated by STR profiling and mycoplasm free) cells containing the SV40 Large T-antigen were cultured and transfected by calcium phosphate method as reported previously (McArthur et al., 2018). In brief, cells were cultured at 37°C, 5% CO₂ in Dulbecco’s modified Eagle’s medium (DMEM, Invitrogen Life Technologies, VIC, Australia), supplemented with 10% fetal bovine serum (FBS, Bovigen, VIC, Australia), 1% GlutaMAX and penicillin-streptomycin (Invitrogen). HEK293T cells were then transiently co-transfected with the different Ca_V channel isoforms and green fluorescent protein (GFP) for visualization, using the calcium phosphate method. cDNAs encoding human Ca_V3.1 (provided by Dr G Zamponi), human Ca_V3.2 (a1Ha-pcDNA3 was a gift from Dr E Perez-Reyes, Addgene #45809) (Cribbs et al., 1998), human Ca_V3.3 (a1Ic-HE3-pcDNA3 also from Dr E Perez-Reyes, Addgene #45810) (Gomora et al., 2002) in combination with GFP. Ca_V3^DII swap constructs and K_V1.7/Ca_V3.3 chimeras were custom synthesized by GeneScript, NJ.

Chinese hamster ovary (CHO) cells were used to express K_V1.7 and K_V1.7-Ca_V3.3 paddle chimeras. Cell culture conditions were the same as the HEK293T cells except DMEM was substituted with DMEM/F12 (Invitrogen). CHO cells were transfected with cDNAs encoding K_V1.7 and K_V1.7/Ca_V3.3^DI-DIV chimeras using Lipofectamine 2000 (Invitrogen) as per the manufacturer’s protocol and used for recordings 12–48 hr post-transfection.

Electrophysiology

Request a detailed protocol

Whole-cell patch clamp configuration was used to record calcium (I_Ca) or potassium (I_K) currents in transiently transfected HEK293T cells. Recordings were made using a MultiClamp 700B amplifier, digitized with a DigiData1440, and controlled using Clampex11.1 software (Molecular Devices, San Jose, CA). Whole-cell currents were sampled at 100 kHz and then filtered to 10 kHz, with leak and capacitive currents subtracted using a −P/4 protocol for Ca²⁺ currents and uncorrected for K⁺ currents. All recordings were series compensated 60–80%. External solution for I_Ca contained in mM: 100 NaCl, 10 CaCl₂, 1 MgCl₂, 5 CsCl, 30 TEA-Cl, 10 D-glucose and 10 HEPES, pH 7.3 with TEA-OH. External solution for I_K contained in mM: 140 NaCl, 5 KCl, 1 MgCl₂, 2 CaCl₂, 10 glucose, and 10 HEPES, pH 7.3 with NaOH. Fire-polished borosilicate (1B150F-4, World Precision Instruments, Sarasota, FL) patch pipettes were used with resistance of 1–3 MΩ. Intracellular recording solution contained as follows (mM): 140 KGluconate, 5 NaCl, 2 MgCl₂, 5 EGTA, and 10 HEPES, pH 7.2 with KOH. Cells were continuously perfused with extracellular solution at a rate of 1.2 ml/min, while toxin application was superfused onto the cell through a capillary tube attached to a syringe pump (2 µl/min), directly onto the cell being recorded.

For experiments on Ca_V3s, all cells were held at −90 mV. To examine the onset of block, test pulses (100 ms, 0.5 Hz) to −20 mV were applied. To generate activation curves, cells were pulsed from −90 to +40 mV in 10 mV increments at 0.5 Hz. SSI curves were generated by measuring the peak current from a test pulse to −20 mV when preceded by a 1 s pre-pulse from −90 to 20 mV (0.1 Hz). Recovery from inactivation curves was produced by varying the time (0–2 s) between two depolarizing pules to −20 mV (P1 200 ms, P2 50 ms).

For experiments on K_V1.7 and Ca_V3.3 DI-IV chimeras, cells were held at −80 mV and activation curves were generated by applying a 50 ms pre-pulse to varying potentials depending on the channel construct examined (K_V1.7 –60 to 90 mV, DI-III 0 to +160 mV, and DIV −120 to +30 mV) followed by a 50 ms test pulse to measure tail currents (K_V1.7 0 mV, DI-III +80 mV, and DIV −20 mV). To measure the onset of Pn3a inhibition, test pulses (50 ms) from a holding potential of −100 mV to a test potential determined for each channel construct (K_V1.7 40 mV, DI-III 120 mV, and DIV 0 mV) were elicited at 0.2 Hz.

Structures and homology modelling of human T-type calcium channels and the docking of Pn3a

Request a detailed protocol

The cryo-EM structures of human Ca_V3.1 (PDB ID: 6KZO) (Zhao et al., 2019) and Ca_V3.3 (PDB ID: 7WLI) (He et al., 2022) were used for docking calculations. The comparative model of humanCa_V3.2 was built upon the cryo-EM structure of hCa_V3.1 in the apo form (PDB ID: 6KZO) via the SWISS-MODEL server (https://swissmodel.expasy.org/). The 3D structure of μ-theraphotoxin (TRTX)-Pn3a (PDB ID: 5T4R) (Deuis et al., 2017) was docked into the three T-type calcium channels via Autodock Vina with a grid box of 40Å × 40Å × 40 Å. We also compared the binding mode and the binding affinity amongst the four VSs of Ca_V3.3, to identify which VS module Pn3a preferentially targets. The docking results were further analysed via Discovery Studio 2017R2 and visualized using Visual Molecular Dynamics (VMD) version 1.9.3 (Humphrey et al., 1996).

Data and statistical analysis

Request a detailed protocol

All data analysis and graphs were generated in OriginPro (Origin Lab Corporation, Northampton, MA). Concentration-response curves were generated by plotting peak current amplitudes in the presence of Pn3a (I_Pn3a), over the current before Pn3a application (I_Control). The resulting curve was fit with a sigmoidal curve according to the following expression:

I_{P n 3 a} / I_{C o n t r o l} = 1 + {[P n 3 a]}^{n} / (I C 50^{n} + {[P n 3 a]}^{n})

where IC50 is the half-maximal inhibitory concentration and n is the Hill coefficient. Activation (Equation 2) and SSI (Equation 3) curves were fit by the modified Boltzmann equation:

I = 1 - 1 / (1 + \exp (\frac{V m - V_{0.5}}{k a}))

G = 1 / (1 + \exp (\frac{V m - V_{0.5}}{k a}))

where I is the current or G is the conductance, V_m is the pre-pulse potential, V_0.5 is the half-maximal activation potential, and ka is the slope factor. Recovery from inactivation plots was fit using a single exponential of the following equation:

(\frac{P 2}{P 1}) = 1 + A_{f a s t} * \exp (- \frac{t}{t})

where τ is the time constant and A is the amplitude. Statistical significance (p<0.05) was determined using paired or unpaired t-test or two-way ANOVA followed by a Tukey multiple comparison test if F achieves the level of statistical significance of p<0.05 and no variance inhomogeneity. All data are presented as mean ± SEM (n), where n is individual cells with all experimental results containing n≥5 individual cells.

Data availability

All data generated or analysed during this study are included in the manuscript and supporting file.

References

(2016) The hitchhiker’s guide to the voltage-gated sodium channel galaxy
The Journal of General Physiology 147:1–24.
https://doi.org/10.1085/jgp.201511492
- PubMed
- Google Scholar
1. Astori S
2. Wimmer RD
3. Prosser HM
4. Corti C
5. Corsi M
6. Liaudet N
7. Volterra A
8. Franken P
9. Adelman JP
10. Lüthi A
(2011) The Ca(V)3.3 calcium channel is the major sleep spindle pacemaker in thalamus
PNAS 108:13823–13828.
https://doi.org/10.1073/pnas.1105115108
- PubMed
- Google Scholar
(2019) New structures and gating of voltage-dependent potassium (Kv) channels and their relatives: a multi-domain and dynamic question
International Journal of Molecular Sciences 20:2.
https://doi.org/10.3390/ijms20020248
- PubMed
- Google Scholar
1. Bladen C
2. Zamponi GW
(2012) Common mechanisms of drug interactions with sodium and T-type calcium channels
Molecular Pharmacology 82:481–487.
https://doi.org/10.1124/mol.112.079715
- PubMed
- Google Scholar
1. Bladen C
2. Hamid J
3. Souza IA
4. Zamponi GW
(2014) Block of T-type calcium channels by protoxins I and II
Molecular Brain 7:36.
https://doi.org/10.1186/1756-6606-7-36
- PubMed
- Google Scholar
(2008) Deconstructing voltage sensor function and pharmacology in sodium channels
Nature 456:202–208.
https://doi.org/10.1038/nature07473
- PubMed
- Google Scholar
1. Bosmans F
2. Swartz KJ
(2010) Targeting voltage sensors in sodium channels with spider toxins
Trends in Pharmacological Sciences 31:175–182.
https://doi.org/10.1016/j.tips.2009.12.007
- PubMed
- Google Scholar
1. Bourinet E
2. Stotz SC
3. Spaetgens RL
4. Dayanithi G
5. Lemos J
6. Nargeot J
7. Zamponi GW
(2001) Interaction of SNX482 with domains III and IV inhibits activation gating of alpha(1E) (Ca(V)2.3) calcium channels
Biophysical Journal 81:79–88.
https://doi.org/10.1016/S0006-3495(01)75681-0
- PubMed
- Google Scholar
(1997) The capsaicin receptor: a heat-activated ion channel in the pain pathway
Nature 389:816–824.
https://doi.org/10.1038/39807
- PubMed
- Google Scholar
1. Catterall WA
(2000) From ionic currents to molecular mechanisms: the structure and function of voltage-gated sodium channels
Neuron 26:13–25.
https://doi.org/10.1016/s0896-6273(00)81133-2
- PubMed
- Google Scholar
(2005) International Union of Pharmacology XLVIII: Nomenclature and structure-function relationships of voltage-gated calcium channels
Pharmacological Reviews 57:411–425.
https://doi.org/10.1124/pr.57.4.5
- PubMed
- Google Scholar
(2007) Voltage-gated ion channels and gating modifier toxins
Toxicon: Journal of the International Society on Toxinology 49:124–141.
https://doi.org/10.1016/j.toxicon.2006.09.022
- PubMed
- Google Scholar
1. Cestèle S
2. Qu Y
3. Rogers JC
4. Rochat H
5. Scheuer T
6. Catterall WA
(1998) Voltage sensor-trapping: enhanced activation of sodium channels by beta-scorpion toxin bound to the S3-S4 loop in domain II
Neuron 21:919–931.
https://doi.org/10.1016/s0896-6273(00)80606-6
- PubMed
- Google Scholar
(1998) Inhibition of T-type voltage-gated calcium channels by a new scorpion toxin
Nature Neuroscience 1:668–674.
https://doi.org/10.1038/3669
- PubMed
- Google Scholar
1. Corzo G
2. Escoubas P
3. Villegas E
4. Karbat I
5. Gordon D
6. Gurevitz M
7. Nakajima T
8. Gilles N
(2005) A spider toxin that induces A typical effect of scorpion alpha-toxins but competes with beta-toxins on binding to insect sodium channels
Biochemistry 44:1542–1549.
https://doi.org/10.1021/bi048434k
- PubMed
- Google Scholar
(1989) Calcium currents in rat thalamocortical relay neurones: kinetic properties of the transient, low-threshold current
The Journal of Physiology 414:587–604.
https://doi.org/10.1113/jphysiol.1989.sp017705
- PubMed
- Google Scholar
1. Cribbs LL
2. Lee JH
3. Yang J
4. Satin J
5. Zhang Y
6. Daud A
7. Barclay J
8. Williamson MP
9. Fox M
10. Rees M
11. Perez-Reyes E
(1998) Cloning and characterization of alpha1H from human heart, a member of the T-type Ca2+ channel gene family
Circulation Research 83:103–109.
https://doi.org/10.1161/01.res.83.1.103
- PubMed
- Google Scholar
1. Deng M
2. Luo X
3. Jiang L
4. Chen H
5. Wang J
6. He H
7. Liang S
(2013) Synthesis and biological characterization of synthetic analogs of Huwentoxin-IV (Mu-theraphotoxin-Hh2a), a neuronal tetrodotoxin-sensitive sodium channel inhibitor
Toxicon 71:57–65.
https://doi.org/10.1016/j.toxicon.2013.05.015
- PubMed
- Google Scholar
1. Deuis JR
2. Dekan Z
3. Wingerd JS
4. Smith JJ
5. Munasinghe NR
6. Bhola RF
7. Imlach WL
8. Herzig V
9. Armstrong DA
10. Rosengren KJ
11. Bosmans F
12. Waxman SG
13. Dib-Hajj SD
14. Escoubas P
15. Minett MS
16. Christie MJ
17. King GF
18. Alewood PF
19. Lewis RJ
20. Wood JN
21. Vetter I
(2017) Pharmacological characterisation of the highly Na_V1.7 selective spider venom peptide Pn3a
Scientific Reports 7:40883.
https://doi.org/10.1038/srep40883
- PubMed
- Google Scholar
1. Dreyfus FM
2. Tscherter A
3. Errington AC
4. Renger JJ
5. Shin HS
6. Uebele VN
7. Crunelli V
8. Lambert RC
9. Leresche N
(2010) Selective T-type calcium channel block in thalamic neurons reveals channel redundancy and physiological impact of I(T)window
The Journal of Neuroscience 30:99–109.
https://doi.org/10.1523/JNEUROSCI.4305-09.2010
- PubMed
- Google Scholar
(2010) Inhibition of the activation pathway of the T-type calcium channel Ca(V)3.1 by ProTxII
Toxicon 56:624–636.
https://doi.org/10.1016/j.toxicon.2010.06.009
- PubMed
- Google Scholar
(2006) Molecular and functional differences between heartMolecular and Functional Differences between Heart mKv1.7 channel isoform Channel Isoforms
The Journal of General Physiology 128:133–145.
https://doi.org/10.1085/jgp.200609498
- PubMed
- Google Scholar
1. Finol-Urdaneta R
2. Remedi MS
3. Raasch W
4. Becker S
5. Clark RB
6. Strüver N
7. Pavlov E
8. Nichols CG
9. French RJ
10. Terlau H
(2012) Block of Kv1.7 potassium currents increases glucose-stimulated insulin secretion
EMBO Molecular Medicine 4:424–434.
https://doi.org/10.1002/emmm.201200218
- PubMed
- Google Scholar
(2020) Marine Toxins Targeting Kv1 channels: pharmacological tools and therapeutic scaffolds
Marine Drugs 18:3.
https://doi.org/10.3390/md18030173
- PubMed
- Google Scholar
1. Finol-Urdaneta RK
2. Ziegman R
3. Dekan Z
4. McArthur JR
5. Heitmann S
6. Luna-Ramirez K
7. Tae HS
8. Mueller A
9. Starobova H
10. Chin YKY
11. Wingerd JS
12. Undheim EAB
13. Cristofori-Armstrong B
14. Hill AP
15. Herzig V
16. King GF
17. Vetter I
18. Rash LD
19. Adams DJ
20. Alewood PF
(2022) Multitarget nociceptor sensitization by a promiscuous peptide from the venom of the King Baboon spider
PNAS 119:5.
https://doi.org/10.1073/pnas.2110932119
- PubMed
- Google Scholar
(2002) Cloning and expression of the human T-type channel Ca(v)3.3: insights into prepulse facilitation
Biophysical Journal 83:229–241.
https://doi.org/10.1016/s0006-3495(02)75164-3
- PubMed
- Google Scholar
1. Gui J
2. Liu B
3. Cao G
4. Lipchik AM
5. Perez M
6. Dekan Z
7. Mobli M
8. Daly NL
9. Alewood PF
10. Parker LL
11. King GF
12. Zhou Y
13. Jordt SE
14. Nitabach MN
(2014) A tarantula-venom peptide antagonizes the TRPA1 nociceptor ion channel by binding to the S1-S4 gating domain
Current Biology 24:473–483.
https://doi.org/10.1016/j.cub.2014.01.013
- PubMed
- Google Scholar
1. Hanck DA
2. Sheets MF
(2007) Site-3 toxins and cardiac sodium channels
Toxicon 49:181–193.
https://doi.org/10.1016/j.toxicon.2006.09.017
- PubMed
- Google Scholar
1. Hansen PBL
(2015) Functional importance of T-type voltage-gated calcium channels in the cardiovascular and renal system: news from the world of knockout mice
American Journal of Physiology. Regulatory, Integrative and Comparative Physiology 308:R227–R237.
https://doi.org/10.1152/ajpregu.00276.2014
- PubMed
- Google Scholar
1. He L
2. Yu Z
3. Geng Z
4. Huang Z
5. Zhang C
6. Dong Y
7. Gao Y
8. Wang Y
9. Chen Q
10. Sun L
11. Ma X
12. Huang B
13. Wang X
14. Zhao Y
(2022) Structure, gating, and pharmacology of human CaV3.3 channel
Nature Communications 13:e28.
https://doi.org/10.1038/s41467-022-29728-0
- Google Scholar
1. Huguenard JR
(1996) Low-threshold calcium currents in central nervous system neurons
Annual Review of Physiology 58:329–348.
https://doi.org/10.1146/annurev.ph.58.030196.001553
- PubMed
- Google Scholar
(1996) VMD: visual molecular dynamics
Journal of Molecular Graphics 14:33–38.
https://doi.org/10.1016/0263-7855(96)00018-5
- PubMed
- Google Scholar
1. Kozlov AS
2. McKenna F
3. Lee JH
4. Cribbs LL
5. Perez-Reyes E
6. Feltz A
7. Lambert RC
(1999) Distinct kinetics of cloned T-type Ca2 + channels lead to differential Ca2 + entry and frequency-dependence during mock action potentials
The European Journal of Neuroscience 11:4149–4158.
https://doi.org/10.1046/j.1460-9568.1999.00841.x
- PubMed
- Google Scholar
1. Kuenzi FM
2. Dale N
(1996) Effect of capsaicin and analogues on potassium and calcium currents and vanilloid receptors in Xenopus embryo spinal neurones
British Journal of Pharmacology 119:81–90.
https://doi.org/10.1111/j.1476-5381.1996.tb15680.x
- PubMed
- Google Scholar
1. Lee JH
2. Daud AN
3. Cribbs LL
4. Lacerda AE
5. Pereverzev A
6. Klöckner U
7. Schneider T
8. Perez-Reyes E
(1999) Cloning and expression of a novel member of the low voltage-activated T-type calcium channel family
The Journal of Neuroscience 19:1912–1921.
https://doi.org/10.1523/JNEUROSCI.19-06-01912.1999
- PubMed
- Google Scholar
1. Lee SE
2. Lee J
3. Latchoumane C
4. Lee B
5. Oh SJ
6. Saud ZA
7. Park C
8. Sun N
9. Cheong E
10. Chen CC
11. Choi EJ
12. Lee CJ
13. Shin HS
(2014) Rebound burst firing in the reticular thalamus is not essential for pharmacological absence seizures in mice
PNAS 111:11828–11833.
https://doi.org/10.1073/pnas.1408609111
- PubMed
- Google Scholar
1. Li-Smerin Y
2. Swartz KJ
(1998) Gating modifier toxins reveal a conserved structural motif in voltage-gated Ca2+ and K+ channels
PNAS 95:8585–8589.
https://doi.org/10.1073/pnas.95.15.8585
- PubMed
- Google Scholar
1. Liu Z
2. Cai T
3. Zhu Q
4. Deng M
5. Li J
6. Zhou X
7. Zhang F
8. Li D
9. Li J
10. Liu Y
11. Hu W
12. Liang S
(2013) Structure and function of hainantoxin-III, a selective antagonist of neuronal tetrodotoxin-sensitive voltage-gated sodium channels isolated from the Chinese bird spider Ornithoctonus hainana
The Journal of Biological Chemistry 288:20392–20403.
https://doi.org/10.1074/jbc.M112.426627
- PubMed
- Google Scholar
1. Maksemous N
2. Blayney CD
3. Sutherland HG
4. Smith RA
5. Lea RA
6. Tran KN
7. Ibrahim O
8. McArthur JR
9. Haupt LM
10. Cader MZ
11. Finol-Urdaneta RK
12. Adams DJ
13. Griffiths LR
(2022) Investigation of CACNA1I cav3.3 dysfunction in hemiplegic migraCav3.3 Dysfunction in Hemiplegic Migraine
Frontiers in Molecular Neuroscience 15:e2820.
https://doi.org/10.3389/fnmol.2022.892820
- Google Scholar
1. McArthur JR
2. Motin L
3. Gleeson EC
4. Spiller S
5. Lewis RJ
6. Duggan PJ
7. Tuck KL
8. Adams DJ
(2018) Inhibition of human N- and T-type calcium channels by an ortho-phenoxyanilide derivative, MONIRO-1
British Journal of Pharmacology 175:2284–2295.
https://doi.org/10.1111/bph.13910
- PubMed
- Google Scholar
(2019) Analgesic transient receptor potential vanilloid-1-active compounds inhibit native and recombinant T-type calcium channels
British Journal of Pharmacology 176:2264–2278.
https://doi.org/10.1111/bph.14676
- PubMed
- Google Scholar
(2020) Spider venom peptide Pn3a inhibition of primary afferent high voltage-activated calcium channels
Frontiers in Pharmacology 11:633679.
https://doi.org/10.3389/fphar.2020.633679
- PubMed
- Google Scholar
(1997a) Voltage-dependent inhibition of N- and P-type calcium channels by the peptide toxin omega-grammotoxin-SIA
Molecular Pharmacology 52:1095–1104.
https://doi.org/10.1124/mol.52.6.1095
- PubMed
- Google Scholar
(1997b) Alteration of P-type calcium channel gating by the spider toxin omega-Aga-IVA
Biophysical Journal 72:2117–2128.
https://doi.org/10.1016/S0006-3495(97)78854-4
- PubMed
- Google Scholar
1. Middleton RE
2. Warren VA
3. Kraus RL
4. Hwang JC
5. Liu CJ
6. Dai G
7. Brochu RM
8. Kohler MG
9. Gao YD
10. Garsky VM
11. Bogusky MJ
12. Mehl JT
13. Cohen CJ
14. Smith MM
(2002) Two tarantula peptides inhibit activation of multiple sodium channels
Biochemistry 41:14734–14747.
https://doi.org/10.1021/bi026546a
- PubMed
- Google Scholar
1. Molineux ML
2. McRory JE
3. McKay BE
4. Hamid J
5. Mehaffey WH
6. Rehak R
7. Snutch TP
8. Zamponi GW
9. Turner RW
(2006) Specific T-type calcium channel isoforms are associated with distinct burst phenotypes in deep cerebellar nuclear neurons
PNAS 103:5555–5560.
https://doi.org/10.1073/pnas.0601261103
- PubMed
- Google Scholar
(2002) Two new scorpion toxins that target voltage-gated Ca2+ and Na+ channels
Biochemical and Biophysical Research Communications 299:562–568.
https://doi.org/10.1016/s0006-291x(02)02706-7
- PubMed
- Google Scholar
1. Park YG
2. Park HY
3. Lee CJ
4. Choi S
5. Jo S
6. Choi H
7. Kim YH
8. Shin HS
9. Llinas RR
10. Kim D
(2010) Ca(V)3.1 is a tremor rhythm pacemaker in the inferior olive
PNAS 107:10731–10736.
https://doi.org/10.1073/pnas.1002995107
- PubMed
- Google Scholar
1. Perez-Reyes E
2. Cribbs LL
3. Daud A
4. Lacerda AE
5. Barclay J
6. Williamson MP
7. Fox M
8. Rees M
9. Lee JH
(1998) Molecular characterization of a neuronal low-voltage-activated T-type calcium channel
Nature 391:896–900.
https://doi.org/10.1038/36110
- PubMed
- Google Scholar
1. Perez-Reyes E
(2003) Molecular physiology of low-voltage-activated t-type calcium channels
Physiological Reviews 83:117–161.
https://doi.org/10.1152/physrev.00018.2002
- PubMed
- Google Scholar
1. Salari A
2. Vega BS
3. Milescu LS
4. Milescu M
(2016) Molecular interactions between tarantula toxins and low-voltage-activated calcium channels
Scientific Reports 6:23894.
https://doi.org/10.1038/srep23894
- PubMed
- Google Scholar
(2007) Molecular interactions of the gating modifier toxin ProTx-II with NaV 1.5: implied existence of a novel toxin binding site coupled to activation
The Journal of Biological Chemistry 282:12687–12697.
https://doi.org/10.1074/jbc.M610462200
- PubMed
- Google Scholar
1. Swartz KJ
2. MacKinnon R
(1997) Mapping the receptor site for hanatoxin, a gating modifier of voltage-dependent K+ channels
Neuron 18:675–682.
https://doi.org/10.1016/s0896-6273(00)80307-4
- Google Scholar
1. Terlau H
2. Shon KJ
3. Grilley M
4. Stocker M
5. Stühmer W
6. Olivera BM
(1996) Strategy for rapid immobilization of prey by a fish-hunting marine snail
Nature 381:148–151.
https://doi.org/10.1038/381148a0
- PubMed
- Google Scholar
1. Zamponi GW
(2016) Targeting voltage-gated calcium channels in neurological and psychiatric diseases
Nature Reviews. Drug Discovery 15:19–34.
https://doi.org/10.1038/nrd.2015.5
- PubMed
- Google Scholar
1. Zhao Y
2. Huang G
3. Wu Q
4. Wu K
5. Li R
6. Lei J
7. Pan X
8. Yan N
(2019) Cryo-EM structures of apo and antagonist-bound human Cav3.1
Nature 576:492–497.
https://doi.org/10.1038/s41586-019-1801-3
- PubMed
- Google Scholar

Decision letter

Henry M Colecraft

Reviewing Editor; Columbia University, United States
Richard W Aldrich

Senior Editor; The University of Texas at Austin, United States

Our editorial process produces two outputs: (i) public reviews designed to be posted alongside the preprint for the benefit of readers; (ii) feedback on the manuscript for the authors, including requests for revisions, shown below. We also include an acceptance summary that explains what the editors found interesting or important about the work.

Decision letter after peer review:

Thank you for submitting your article "µ-Theraphotoxin-Pn3a inhibition of Cav3.3 channels reveals a novel isoform-selective drug binding site" for consideration by eLife. Your article has been reviewed by 3 peer reviewers, one of whom is a member of our Board of Reviewing Editors, and the evaluation has been overseen by Richard Aldrich as the Senior Editor. The reviewers have opted to remain anonymous.

The reviewers have discussed their reviews with one another, and the Reviewing Editor has drafted this to help you prepare a revised submission.

Essential revisions:

1) There are some complexities associated with interpretation of the data obtained using Kv1.7/CaV3.3 VSD chimeras. Chimeras between Cav3.1 and Cav3.3 where entire membrane domains were swapped are in the public domain. CaV3.1/CaV3.3 chimeras with VSDII swapped (or similar chimera) should be done to strengthen the idea that Pn3a inhibits CaV3.3 by binding to VSDII.

2) Several residues in CaV3.3 are proposed to mediate selective inhibition by Pn3a based on MD simulations. These predictions should be validated by mutagenesis and functional experiments.

3) Pn3a blocks various CaV1/2 channels and NaV1.7. The latter is particularly high affinity (nM range) compared to CaV3.3 (uM). This limitation is noted briefly in lines 314-316. The authors should expand this further for the general audience who may be interested in using this toxin practically.

Reviewer #1 (Recommendations for the authors):

1. It seems surprising that the scaled Pn3a-inhibited CaV3.3 currents displayed the same activation kinetics but slower inactivation compared to uninhibited channels (Figure 1). Intuitively, the inhibitory effect of Pn3a would appear to be more consistent with slower activation and faster inactivation kinetics. Single channel experiments would be needed to distinguish these two different interpretations which could both give rise to similar macroscopic currents.

2. The effects of Pn3a on CaV3.3 gating should be modeled to provide deepened insights into the possible mechanisms of action that can explain the data.

3. Does Pn3a inhibit the maximal CaV3.3 current amplitude? The use of normalized G-V curves obscures this important point. The impact of Pn3a on Gmax should be provided.

4. The computational docking model (Figure 6) should be validated by mutagenesis experiments.

5. A significant rationale for the paper was the idea that Pn3a could potentially be used to distinguish CaV3.3-mediated effects from those of co-expressed CaV3.3 and CaV3.2 in native tissues. This capability certainly would certainly be a significant achievement. This prediction would need to be tested in a native cell type expressing multiple CaV3 channel isoforms. However, previous reports that Pn3a also inhibits Nav1.7 and HVA Ca channels suggest that interpreting the effects of the toxin in native cells is likely to be highly complicated.

Reviewer #2 (Recommendations for the authors):

The electrophysiological analysis of CaV3.x comparing the effect of Pn3a is well done and convincing. As noted in the public review, the main weakness is that the mechanism by why Pn3a accomplishes this selectivity is not fully clear and the identification of specific residues that support Pn3a interaction relies solely on computational docking.

1. The mechanisms that confer subtype specificity of Pn3a for CaV3.3 is not clear. The docking simulation suggests that Pn3a interacts with both CaV3.2 and CaV3.3 at slightly distinct residues on the same, but only CaV3.3 is inhibited. Is there any experimental evidence that shows that Pn3a binds to CaV3.1/CaV3.2 VSDs? Also the docking seems to suggest that Pn3a interacts with all 4 VSDs of CaV3.3. However, the Kv chimeras suggest that it modulates only VSDII and VSDIII. How does one reconcile these findings? Is it that Pn3a interaction with VSDI and VSDIV does not impede movement of these VSD? Or is it that these are only weak interactions that are not relevant physiologically?

2. Several residues in CaV3.3 are proposed to mediate selective inhibition by Pn3a, however these are all based on MD simulations. It would considerably strengthen the study to provide complementary electrophysiological data either disrupting these sites (or enabling them on CaV3.1/3.2) to confirm the role of these sites experimentally.

3. One of the important advances here is that Pn3a is shown to be subtype selective for CaV3.3. Nonetheless, this toxin also blocks various CaV1/2 channels and NaV1.7. The latter is particularly high affinity (nM range) compared to CaV3.3 (uM). This limitation is noted briefly in lines 314-316. It may be helpful to expand this further for the general audience who may be interested in using this toxin practically.

Reviewer #3 (Recommendations for the authors):

Abstract: I am not sure that the authors are correct in saying that we do not know much about the physiological roles of Cav3.3 – there are channelopathies associated with this isoform, and there is a KO mouse that has yielded some very interesting data. Indeed, the authors acknowledge these studies in the introduction. Please tone down this statement in the abstract. No sure I agree that the S3-4 region necessarily has therapeutic potential – it will be difficult to target this site with small organic molecules – maybe stick with the molecular tool aspect instead.

Introduction- more information about the animal species of the various toxins that are discussed should be given.

Line 90 – introduction – maybe also include grammotoxin (Bean lab) here, and SNX482 (Bourinet lab) here as gating modifiers.

Line 137: Instead of referring to faster tau values, please use the term "time constants" (this also applies to others spots in the manuscript).

Line 156: At several points in the manuscript the authors use terms such as "Cav3.3's gating" – I think it would read better if this stated the "gating of Cav3.3".

Figure 2 – can you please also include IV curves rather than only the activation curves – it would allow the authors to reinforce the observed shift in the voltage dependence of activation.

Figure 2 – while the authors may be correct in assuming that there is faster recovery from inactivation with the toxin, these data could potentially be contaminated in the early phase by voltage-dependent unbinding of the toxin in response to the depolarizing pulses that are given – please recall the classical agaIVA recovery experiment from Bruce Bean's lab and also seen with SNX. It is entirely possible that the observed recovery appears accelerated because the channel not only recovers from inactivation, but also recovers from block as a result of a train of depolarizations (consistent with Figure 3).

Figure 4 title – there must be a missing word.

Figure 5 – Major point: although these data are consistent with an effect of DII VSD, one thing to keep in mind and point out clearly is that the K channel has four fold symmetry, and in these chimeras you essentially now have four Cav3.3 toxin target sites – and yet, the effect of the toxin on voltage dependence of activation of this chimera is about the same as what is observed in the Cav3.3 WT channels, suggesting that things are a bit more complicated than the reader is being led to believe. Furthermore, the chimera has completely screwed up voltage dependence of activation (i.e., 100 mV depolarized) which is problematic as this indicates that this chimera has some major structural problems. This also applies to all of the other chimeras. I think that the authors need to consider making at least one reverse chimera of Cav3.3 where Domain II VSD is replaced by either sequence from Kv1.7 or better yet, Cav3.2 or Cav3.1. Indeed, chimeras between Cav3.1 and Cav3.3 where entire membrane domains were swapped are in the public domain and may be available to the authors. I think data on a GIGG and IGII chimera pair would really add to the story. Overall, I am a little bit puzzled as to why a K channel was used fro this when the authors clearly see a large Cav3 isoform dependence and their docking model indicates that Cav3.2 can't interact the same way as Cav3.3.

Figure 6 – why is the toxin docked to all four voltage sensing domains of Cav3.3 – are the authors saying that the toxin binds to four sites simultaneously, but affects gating by only acting on DII?

In conclusion, it is a nice study, but the potassium channel backbone that is used has potential issues, not only because of the four fold symmetry, but also because of the mightily screwed up gating – you should really at least try to do a minimal set of experiments with a Cav3.1/Cav3.2-Cav3.3 chimera.

[Editors' note: further revisions were suggested prior to acceptance, as described below.]

Thank you for resubmitting your work entitled "µ-Theraphotoxin-Pn3a inhibition of Cav3.3 channels reveals a novel isoform-selective drug binding site" for further consideration by eLife. Your revised article has been evaluated by Richard Aldrich (Senior Editor) and a Reviewing Editor.

The manuscript has been improved but there are some remaining issues that need to be addressed, as outlined below:

Reviewer 2 has raised pertinent questions regarding complexities in correlating the electrophysiological experiments with MD simulations as it relates to the contributions of residues D689A and Q687A that can be addressed by discussion.

Reviewer #2 (Recommendations for the authors):

The revised manuscript has several new experiments that have strengthened the study – in particular, the chimeric experiments with CaV3.1/3.2 and CaV3.3 are insightful in deducing that DII plays a key role in binding the toxin and that this is the reason for selectivity. The mutagenesis studies are also helpful and have improved the study as a whole.

One complexity is that the correlation of electrophysiological experiments with MD simulations seems to be not as clear-cut. For instance, D689 is an important contributor in electrophysiology recordings, yet the only contact with Pn3a seems to be through backbone carbonyl which would be seemingly preserved with an alanine mutation. So, it is not fully clear why D689A has an effect while another mutation Q687A where the Q interacts with a charged residue seems to have minimal effect. Perhaps part of this is because the CaV3.1 VSDII is presumably in the up-state while Pn3a affinity is stronger in the down-state. And the orientation/accessibility of these residues may be somewhat different in the up versus down-state. It may be helpful to explicitly note what state VSD II is in for the simulations and also to briefly discuss some of these caveats.

Reviewer #3 (Recommendations for the authors):

Great job on the revisions. I have no further suggestions.

https://doi.org/10.7554/eLife.74040.sa1

Author response

Essential revisions:

1) There are some complexities associated with interpretation of the data obtained using Kv1.7/CaV3.3 VSD chimeras. Chimeras between Cav3.1 and Cav3.3 where entire membrane domains were swapped are in the public domain. CaV3.1/CaV3.3 chimeras with VSDII swapped (or similar chimera) should be done to strengthen the idea that Pn3a inhibits CaV3.3 by binding to VSDII.

A new set of experiments was performed with Cav3 domain II swap constructs including Cav3.3/Cav3.1^DII, Cav3.3/Cav3.2^DII, Cav3.1/Cav3.3^DII, and Cav3.2/Cav3.3^DII.

Consistent with the observations made in the Kv1.7/Cav3.3^DII system, data obtained from Cav3 domain II swap constructs supported the importance of Cav3.3^DII for Pn3a’s selective inhibition of Cav3.3. Grafting Cav3.3^DII onto Cav3.1 or Cav3.2 results in Pn3a-sensitive channels, whilst inhibition is significantly decreased when Cav3.1^DII (p < 0.0001) or Cav3.2^DII (p < 0.0001) are inserted into the Cav3.3 backbone. This data is now summarised in Figure 6E.

2) Several residues in CaV3.3 are proposed to mediate selective inhibition by Pn3a based on MD simulations. These predictions should be validated by mutagenesis and functional experiments.

The predictions of the computational model of Pn3a/Cav3.3 were examined through 7 different point mutations made in Cav3.3 (Figure 6E), and three of those were further verified in the Kv1.7/Cav3.3^DII system (Figure 5—figure supplement 1). From these new data sets, it can be surmised that D689 located in Cav3.3^DI is a key determinant of Pn3a’s affinity towards Cav3.3 with a modest contribution from E628.

3) Pn3a blocks various CaV1/2 channels and NaV1.7. The latter is particularly high affinity (nM range) compared to CaV3.3 (uM). This limitation is noted briefly in lines 314-316. The authors should expand this further for the general audience who may be interested in using this toxin practically.

We have now included additional details on Pn3a targeting of Nav and Cav channels (lines 314-319).

Reviewer #1 (Recommendations for the authors):

1. It seems surprising that the scaled Pn3a-inhibited CaV3.3 currents displayed the same activation kinetics but slower inactivation compared to uninhibited channels (Figure 1). Intuitively, the inhibitory effect of Pn3a would appear to be more consistent with slower activation and faster inactivation kinetics. Single channel experiments would be needed to distinguish these two different interpretations which could both give rise to similar macroscopic currents.

We calculated the macroscopic activation and inactivation time constants from the inhibition of Cav3.3 at -20 mV by 3 µM Pn3a (Lines 126-128). There was a modest slowing of inactivation: τ_inact control = 39.91 ± 8.25 ms vs τ_inact, Pn3a = 60.25 ± 16.02 ms; P = 0.04, n = 5, paired t-test. The small ~+10mV shift in Cav3.3 activation would have a modest effect on the time constant of activation and we may not be able to resolve this slowing (τ_act, control = 5.95 ± 0.54 ms vs τ_act, Pn3a = 6.37 ± 0.44 ms; P = 0.32, n = 5, paired t-test). The inactivation of Cav3.3 is highly dependent on Ca²⁺ influx and the Pn3a effect on recovery from inactivation may lead to the observed modest slowing of macroscopic inactivation.

2. The effects of Pn3a on CaV3.3 gating should be modeled to provide deepened insights into the possible mechanisms of action that can explain the data.

We appreciate Reviewer #1’s insightful suggestion and we will take it into account for follow-up studies.

3. Does Pn3a inhibit the maximal CaV3.3 current amplitude? The use of normalized G-V curves obscures this important point. The impact of Pn3a on Gmax should be provided.

Pn3a inhibits Cav3.3’s maximal current amplitude as shown in Figures 1A and 2A. As suggested, we have included dashed lines in Figure 2C to indicate the relative inhibitory effects of Pn3a

4. The computational docking model (Figure 6) should be validated by mutagenesis experiments.

We have validated the computational docking model through seven alanine point changes in Cav3.3 mutants and three chimeric constructs. Results of these new experiments are now presented in Figures 6E and Figure 5—figure supplement 1.

5. A significant rationale for the paper was the idea that Pn3a could potentially be used to distinguish CaV3.3-mediated effects from those of co-expressed CaV3.3 and CaV3.2 in native tissues. This capability certainly would certainly be a significant achievement. This prediction would need to be tested in a native cell type expressing multiple CaV3 channel isoforms. However, previous reports that Pn3a also inhibits Nav1.7 and HVA Ca channels suggest that interpreting the effects of the toxin in native cells is likely to be highly complicated.

Although beyond the scope of this research, follow-up studies in native tissues will ascertain the practical utility of Pn3a as a tool for the study of T-type currents mediated by Cav3.3. Much like for many other peptides and small molecules commonly used as molecular tools in the analysis of native currents, selectivity is seldom perfect (ie SNX482, 4AP, etc) and therefore the optimal experimental conditions enabling the exploitation of Pn3a’s selectivity for Cav3.3 would require optimization. These would need to take into account the specific tissue/cells in which the experiments would be performed, adequate pulse protocols (ie to remove HVA calcium channel contribution), as well as incorporating other known inhibitors such as TTX (to effectively block most Navs).

Reviewer #2 (Recommendations for the authors):

The electrophysiological analysis of CaV3.x comparing the effect of Pn3a is well done and convincing. As noted in the public review, the main weakness is that the mechanism by why Pn3a accomplishes this selectivity is not fully clear and the identification of specific residues that support Pn3a interaction relies solely on computational docking.

1. The mechanisms that confer subtype specificity of Pn3a for CaV3.3 is not clear. The docking simulation suggests that Pn3a interacts with both CaV3.2 and CaV3.3 at slightly distinct residues on the same, but only CaV3.3 is inhibited. Is there any experimental evidence that shows that Pn3a binds to CaV3.1/CaV3.2 VSDs? Also the docking seems to suggest that Pn3a interacts with all 4 VSDs of CaV3.3. However, the Kv chimeras suggest that it modulates only VSDII and VSDIII. How does one reconcile these findings? Is it that Pn3a interaction with VSDI and VSDIV does not impede movement of these VSD? Or is it that these are only weak interactions that are not relevant physiologically?

We apologize for the confusion caused by the early version of Figure 6A, in which Pn3a appears docked onto all four VSDs as was evaluated computationally. From the docking calculations, it was observed that the binding of Pn3a to Cav3.3^DII was the most energetically favourable (Figure 6—figure supplement 3) interaction observed. Consistently, electrophysiological assessment of DII swapped Cav3 constructs and Kv1.7/Cav3.3 chimeras verified that the region that enables Pn3a to inhibit Cav3.3 specifically is Cav3.3^DII and therefore Figure 6A was revised to reflect these results and enhance clarity.

2. Several residues in CaV3.3 are proposed to mediate selective inhibition by Pn3a, however these are all based on MD simulations. It would considerably strengthen the study to provide complementary electrophysiological data either disrupting these sites (or enabling them on CaV3.1/3.2) to confirm the role of these sites experimentally.

We appreciate the suggestion and have accordingly generated point mutations in Cav3.3^DII based on the MD docking calculations. These results revealed that Cav3.3DII residue D689 is important for Cav3.3/Pn3a interaction, and to a lesser extent E628, as suggested by reduced Pn3a’s inhibition observed for these mutants (Figure 6E).

3. One of the important advances here is that Pn3a is shown to be subtype selective for CaV3.3. Nonetheless, this toxin also blocks various CaV1/2 channels and NaV1.7. The latter is particularly high affinity (nM range) compared to CaV3.3 (uM). This limitation is noted briefly in lines 314-316. It may be helpful to expand this further for the general audience who may be interested in using this toxin practically.

As above, we have expanded this section to include the affinity and selectivity currently known for Pn3a on both Nav and Cav channels and as discussed further in Lines 452-460.

Reviewer #3 (Recommendations for the authors):

Abstract: I am not sure that the authors are correct in saying that we do not know much about the physiological roles of Cav3.3 – there are channelopathies associated with this isoform, and there is a KO mouse that has yielded some very interesting data. Indeed, the authors acknowledge these studies in the introduction. Please tone down this statement in the abstract. No sure I agree that the S3-4 region necessarily has therapeutic potential – it will be difficult to target this site with small organic molecules – maybe stick with the molecular tool aspect instead.

We appreciate this constructive criticism and have revised the abstract and general message accordingly.

Introduction- more information about the animal species of the various toxins that are discussed should be given

We have now included scientific names for all the species addressed in the introduction.

Line 90 – introduction – maybe also include grammotoxin (Bean lab) here, and SNX482 (Bourinet lab) here as gating modifiers

We have added grammotoxin and SNX482 with appropriate references to line 90.

Line 137: Instead of referring to faster tau values, please use the term "time constants" (this also applies to others spots in the manuscript)

Corrected Lines 137 and 190.

Line 156: At several points in the manuscript the authors use terms such as "Cav3.3's gating" – I think it would read better if this stated the "gating of Cav3.3".

Corrected.

Figure 2 – can you please also include IV curves rather than only the activation curves – it would allow the authors to reinforce the observed shift in the voltage dependence of activation

We have now included the I-V curves in Figure 2A-1

Figure 2 – while the authors may be correct in assuming that there is faster recovery from inactivation with the toxin, these data could potentially be contaminated in the early phase by voltage-dependent unbinding of the toxin in response to the depolarizing pulses that are given – please recall the classical agaIVA recovery experiment from Bruce Bean's lab and also seen with SNX. It is entirely possible that the observed recovery appears accelerated because the channel not only recovers from inactivation, but also recovers from block as a result of a train of depolarizations (consistent with Figure 3)

While the depolarization required for both AgaIVA and SNX482 recovery was fairly large, the observed voltage dependence of Pn3a inhibition may contribute to the observed increased recovery from inactivation. We have now added this caveat in the discussion (lines 377-382).

Figure 4 title – there must be a missing word

Updated to read “Figure 4. Chimeric constructs of the K_V1.7 channel with the Ca_V3.3 voltage sensor paddles.”

Figure 5 – Major point: although these data are consistent with an effect of DII VSD, one thing to keep in mind and point out clearly is that the K channel has four fold symmetry, and in these chimeras you essentially now have four Cav3.3 toxin target sites – and yet, the effect of the toxin on voltage dependence of activation of this chimera is about the same as what is observed in the Cav3.3 WT channels, suggesting that things are a bit more complicated than the reader is being led to believe. Furthermore, the chimera has completely screwed up voltage dependence of activation (i.e., 100 mV depolarized) which is problematic as this indicates that this chimera has some major structural problems. This also applies to all of the other chimeras. I think that the authors need to consider making at least one reverse chimera of Cav3.3 where Domain II VSD is replaced by either sequence from Kv1.7 or better yet, Cav3.2 or Cav3.1. Indeed, chimeras between Cav3.1 and Cav3.3 where entire membrane domains were swapped are in the public domain and may be available to the authors. I think data on a GIGG and IGII chimera pair would really add to the story. Overall, I am a little bit puzzled as to why a K channel was used fro this when the authors clearly see a large Cav3 isoform dependence and their docking model indicates that Cav3.2 can't interact the same way as Cav3.3

We have now included data on the inhibition by Pn3a on the Cav3.3/Cav3.1^DII (IGII), Cav3.1/Cav3.3^DII (GIGG) as well as Cav3.3/Cav3.2^DII (IHII) and Cav3.2/Cav3.3^DII (HIHH). This new data highlights that Cav3.3^DII is critical for specific Pn3a interactions with Cav3.3.

Figure 6 – why is the toxin docked to all four voltage sensing domains of Cav3.3 – are the authors saying that the toxin binds to four sites simultaneously, but affects gating by only acting on DII?

Thank you for pointing this out. We initially modelled Pn3a interactions with all four domains of Cav3.3, to show that Pn3a preferentially targeted DII. We have updated Figure 6A to include only the most energetically favoured interaction site on Cav3.3^DII.

In conclusion, it is a nice study, but the potassium channel backbone that is used has potential issues, not only because of the four fold symmetry, but also because of the mightily screwed up gating – you should really at least try to do a minimal set of experiments with a Cav3.1/Cav3.2-Cav3.3 chimera

[Editors' note: further revisions were suggested prior to acceptance, as described below.]

Reviewer #2 (Recommendations for the authors):

The revised manuscript has several new experiments that have strengthened the study – in particular, the chimeric experiments with CaV3.1/3.2 and CaV3.3 are insightful in deducing that DII plays a key role in binding the toxin and that this is the reason for selectivity. The mutagenesis studies are also helpful and have improved the study as a whole.

One complexity is that the correlation of electrophysiological experiments with MD simulations seems to be not as clear-cut. For instance, D689 is an important contributor in electrophysiology recordings, yet the only contact with Pn3a seems to be through backbone carbonyl which would be seemingly preserved with an alanine mutation. So, it is not fully clear why D689A has an effect while another mutation Q687A where the Q interacts with a charged residue seems to have minimal effect. Perhaps part of this is because the CaV3.1 VSDII is presumably in the up-state while Pn3a affinity is stronger in the down-state. And the orientation/accessibility of these residues may be somewhat different in the up versus down-state. It may be helpful to explicitly note what state VSD II is in for the simulations and also to briefly discuss some of these caveats.

We agree with Reviewer #2 in the limitations of reconciling functional observations of dynamic proteins (such as voltage-gated ion channels) and computational predictions made from homology models of, comparatively static, structures. The Cryo-EM structure of human Cav3.3 Cryo-EM became available during the revisions of our manuscript (Nat Commun. 2022 Apr 19;13(1):2084). Structural alignment revealed that the Cav3.3 (7WLI) and Cav3.1 (6KZO) voltage sensor domains appear to be in similar configurations with an RMSD (for Cα-pairs of VSD, SF, and ECLs) of 1.4 Å (He et al., 2022).

We performed new computational modelling using Cav3.3 Cryo-EM structure to assess the interactions with Pn3a. This new modelling data is consistent with the establishment of key interactions between Pn3a’s residue K17 and Cav3.3DII’s D689 (potentially through the formation of a salt bridge) as well as D689, thereby reconciling our mutagenesis results and modelling predictions. The updated Cav3.3-Pn3a binding model is now reflected in the revised Figure 6 and its supporting figures, and accordingly described/discussed in methods, results and discussion.

https://doi.org/10.7554/eLife.74040.sa2

Article and author information

Author details

Jeffrey R McArthur

Illawarra Health and Medical Research Institute, University of Wollongong, Wollongong, Australia

Contribution
Conceptualization, Resources, Data curation, Formal analysis, Funding acquisition, Validation, Investigation, Visualization, Methodology, Writing - original draft, Project administration, Writing - review and editing

For correspondence
jeffreym@uow.edu.au

Competing interests
No competing interests declared

"This ORCID iD identifies the author of this article:" 0000-0002-2546-7913
Jierong Wen

School of Science, RMIT University, Melbourne, Australia

Contribution
Data curation, Formal analysis, Investigation, Visualization, Writing - review and editing

Competing interests
No competing interests declared
Andrew Hung

School of Science, RMIT University, Melbourne, Australia

Contribution
Conceptualization, Resources, Data curation, Software, Formal analysis, Supervision, Funding acquisition, Validation, Investigation, Visualization, Methodology, Writing - original draft, Project administration, Writing - review and editing

Competing interests
No competing interests declared

"This ORCID iD identifies the author of this article:" 0000-0003-3569-2951
Rocio K Finol-Urdaneta

Illawarra Health and Medical Research Institute, University of Wollongong, Wollongong, Australia

Contribution
Conceptualization, Data curation, Visualization, Writing - original draft, Writing - review and editing

Competing interests
No competing interests declared

"This ORCID iD identifies the author of this article:" 0000-0003-2157-4532
David J Adams

Illawarra Health and Medical Research Institute, University of Wollongong, Wollongong, Australia

Contribution
Conceptualization, Resources, Supervision, Funding acquisition, Project administration, Writing - review and editing

Competing interests
No competing interests declared

"This ORCID iD identifies the author of this article:" 0000-0002-7030-2288

Funding

Rebecca L. Cooper Medical Research Foundation (PG2019396)

Jeffrey R McArthur

National Health and Medical Research Council (APP1072113)

David J Adams

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Acknowledgements

We are grateful to Alexander Mueller (PhD, Vetter laboratory at the Institute of Molecular Bioscience, University of Queensland) for synthesizing the µ-Theraphotoxin Pn3a used in this research. This work was supported by the Rebecca Cooper Foundation for Medical Research Project Grant (PG2019396) to JRM and the National Health and Medical Research Council (NHMRC) Program Grant (APP1072113) to DJA. JRM and RKF-U are grateful to Emma and Zack O Yepugas for continuous support. Computational resources were provided by the National Computational Infrastructure (NCI) which is funded by the Australian Government, and the Pawsey Supercomputing Centre which is funded by the Australian Government and the Government of Western Australia. We acknowledge PRACE for awarding access to the Piz Daint cluster at the Swiss National Supercomputing Centre (CSCS), Switzerland.

Senior Editor

Richard W Aldrich, The University of Texas at Austin, United States

Reviewing Editor

Henry M Colecraft, Columbia University, United States

Publication history

Received: September 20, 2021
Preprint posted: October 4, 2021 (view preprint)
Accepted: July 19, 2022
Accepted Manuscript published: July 20, 2022 (version 1)
Version of Record published: August 1, 2022 (version 2)

Copyright

This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.

Metrics

550

Page views
185

Downloads
0

Citations

Article citation count generated by polling the highest count across the following sources: Crossref, PubMed Central, Scopus.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Mendeley

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

Jeffrey R McArthur
Jierong Wen
Andrew Hung
Rocio K Finol-Urdaneta
David J Adams

(2022)

µ-Theraphotoxin Pn3a inhibition of Ca_V3.3 channels reveals a novel isoform-selective drug binding site

eLife 11:e74040.

https://doi.org/10.7554/eLife.74040

Categories and tags

Research organism

Human

Share this article

Cite this article

Pn3a preferentially inhibits human CaV3.3-mediated Ca2+ currents.

Figure 1—source data 1

Pn3a produces a depolarizing shift in the voltage dependence of activation and speeds up recovery from inactivation of CaV3.3.

Figure 2—source data 1

Activation and inactivation values of CaV3.3 and Kv1.7-CaV3.3DI-IV chimers in the absence (control) and presence of Pn3a (3 µM for CaV3.3; 1 µM for KV1.7-CaV3.3D1-IV chimeras).

Pn3a inhibition of CaV3.3 is stronger at hyperpolarized potentials and speeds up channel deactivation.

Figure 3—source data 1

Chimeric constructs of the KV1.7 channel with the CaV3.3 voltage sensor paddles.

Pn3a shifts the activation of KV1.7/CaV3.3DII chimeric channels.

Figure 5—source data 1

Pn3a and CaV3.3 interactions and subtype specificity.

Figure 6—source data 1

Author details

Jeffrey R McArthur

Contribution

For correspondence

Competing interests

Jierong Wen

Contribution

Competing interests

Andrew Hung

Contribution

Competing interests

Rocio K Finol-Urdaneta

Contribution

Competing interests

David J Adams

Contribution

Competing interests

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

Categories and tags

Research organism

Pn3a preferentially inhibits human Ca_V3.3-mediated Ca²⁺ currents.

Pn3a produces a depolarizing shift in the voltage dependence of activation and speeds up recovery from inactivation of Ca_V3.3.

Activation and inactivation values of Ca_V3.3 and K_v1.7-Ca_V3.3^DI-IV chimers in the absence (control) and presence of Pn3a (3 µM for Ca_V3.3; 1 µM for K_V1.7-Ca_V3.3^D1-IV chimeras).

Pn3a inhibition of Ca_V3.3 is stronger at hyperpolarized potentials and speeds up channel deactivation.

Chimeric constructs of the K_V1.7 channel with the Ca_V3.3 voltage sensor paddles.

Pn3a shifts the activation of K_V1.7/Ca_V3.3^DII chimeric channels.

Pn3a and Ca_V3.3 interactions and subtype specificity.